
Building judgment and adaptability to navigate AI, gene therapy, and constant change.

Veeral Sheth, MD, MBA, FASRS, FACS, is a Chicago native specializing in diseases of the retina and vitreous. He serves as a clinical assistant professor at the University of Illinois at Chicago and is a partner at University Retina, where he directs one of the nation’s busiest clinical trial programs.
Sheth completed his ophthalmology residency at the Illinois Eye and Ear Infirmary, where he served as chief resident, followed by a fellowship in vitreoretinal surgery at the University of Chicago. He also earned an MBA from Northwestern University’s Kellogg School of Management.
As director of clinical trials, Sheth has served as principal investigator on more than 100 clinical trials, advancing therapies for age-related macular degeneration, diabetic retinopathy, retinal vein occlusion, and surgical pathology. His work has been instrumental in the development of new drugs, delivery systems, and gene therapies, helping shape the current and future landscapes of retinal care. He has authored numerous peer-reviewed publications in leading journals, presented extensively at international meetings, and continues to mentor the next generation of retinal specialists.
Sheth is an active member of several professional societies, including the American Society of Retina Specialists (ASRS), The Retina Society, the American Academy of Ophthalmology, the Association for Research in Vision and Ophthalmology, and the European Society of Retina Specialists. In recognition of his contributions, he has received multiple honors, including the Senior Honor Award from the ASRS.

Building judgment and adaptability to navigate AI, gene therapy, and constant change.

OLN324 outperformed faricimab on anatomic outcomes as early as week 1 in the JADE trial, with no cases of intraocular inflammation across both dose groups.